Headquartered in Montreal, Enobia Pharma is a privately held company founded in 1997. The company’s mission is to develop therapies for the treatment of serious neglected diseases affecting the skeletal system, for which no treatment exist. These diseases are the result of an imbalance of specific enzymes that affect bone growth. Using a proprietary bone-targeted form of recombinant alkaline phosphatase, the first program of Enobia is the development of compounds to treat hypophosphatasia.
2901 Rachel Street East, Suite 23
Montreal, Quebec, Canada
Telephone: (514) 596-2901
Fax: (514) 596-2749